Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The World Hip Trauma Evaluation Four (WHiTE Four) study has now opened for recruitment in its first two sites (Northumbria Specialist Emergency Care Hospital in Northumberland, and John Radcliffe Hospital in Oxford). The study is a multi-centre, multi-surgeon, parallel, two arm, randomised controlled trial that will be running in 8+ hospitals in the UK. It is embedded within the WHiTE Comprehensive Cohort Study. The study includes a two-way superiority comparison between the X-Bolt Hip System (XHS) and Sliding Hip Screw fixations, and patients who present to A&E with a trochanteric fracture of the hip, who are 60 years of age and older, are eligible to participate. The trial will last a total of 38 months, with participant recruitment taking 18 months and final follow-up at 12 months post-surgery. Based upon 2013 data in the National Hip Fracture Database, the involved units perform approximately 800 of such procedures per year. The trial’s primary outcome is to quantify and draw inferences on observed differences in participants’ health status between the trial treatment groups at 4 months post-injury, and the secondary outcomes are to quantify and draw inferences on observed differences in the risk of all cause revision surgery, and  in the proportion of complications/radiographic changes within the first year post-injury between the trial treatment groups. 

For more information please visit https://www.ndorms.ox.ac.uk/clinical-trials/current-trials-and-studies/white 

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.